A paper that has recently been published looks into the safety and efficacy of treating patients with active rheumatoid arthritis with umbilical cord mesenchymal stem cells (UC-MSCs).
172 patients were divided into 2 groups. One group received disease modifying drugs plus medium without UC-MSCs and the other received disease modifying drugs plus UC-MSCs. The trial indicated that treatment with disease modifying drugs plus UC-MSCs may provide safe, significant and persistent clinical benefits for patients with active rheumatoid arthritis.
For more on this article click here